Építés alatt – nem éles oldal
Belépés
Csak meghívásos2. fázis

MDMA Plus Exposure Therapy for PTSD

A legfontosabb adatok

Ki végzi
Emory University
Hol
Atlanta (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Csak meghívásos
Fázis
2. fázis
Résztvevők
40 fő, tervezett
Kezdés
2024. febr. 13.
Tervezett befejezés
2026. okt. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • MDMA
A regiszteradat frissítve
2026. július 8.

Ki vehet részt

Életkor
21 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Meet criteria for PTSD
  • Willingness of the participant to sign a release for the investigators to communicate with their primary care or mental health providers if indicated
  • Are able to visually read and understand the English language and give written informed consent
  • Are able to swallow pills
  • Agree to have study visits and treatment sessions video and/or audio recorded,
  • Must provide a contact (relative, spouse, close friend, or another support person) who is willing and able to be reached by the investigators
  • Must agree to inform the investigators within 48 hours of any medical conditions and procedures
  • If able to become pregnant, must have a negative pregnancy test prior to study entry, at study entry, and prior to the Medicine Session. Must agree to use adequate birth control for a month prior to the Medicine session and through 10 days after the Medicine session
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Medicine Session, and not participate in any other interventional clinical trials during the duration of the study and are driven home or to a hotel after the Medicine Session, and commit to medication dosing, therapy, and study procedures

Ki nem vehet részt

  • Have previously participated in a Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored MDMA clinical trial
  • Have a history of any medical condition that could make receiving MDMA dangerous because of increases in blood pressure and heart rate or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism is exclusionary
  • Require the use of concomitant medications that could impact the effects or safety of MDMA during the Medicine Session
  • Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment
  • Have hypersensitivity to any ingredient of the Investigational Medicinal Product (IMP)
  • Upon review of medical or psychiatric history and assessment, have any current or past diagnosis that would be considered a risk to participating in the study
  • Requires ongoing psychiatric medication use with certain exceptions. Individuals may decide to taper psychiatric medications under the guidance of their local provider
  • Have any unstable medical condition that would interfere with participation
  • Have uncontrolled hypertension) documented on three separate occasions
  • Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation
  • Have a history of ever having ventricular arrhythmia or any other abnormal heart rhythm that the study physician believes would pose a significant risk of participation
  • Have symptomatic liver disease or significant liver enzyme elevations
  • Have a history of hyponatremia or hyperthermia
  • Have a history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Are not able to give adequate informed consent
  • Have any current problem which, in the opinion of the investigator or study physician might interfere with participation
  • Current or past substance abuse that would be considered a risk for participating in the study
  • Have an abnormal finding on electrocardiogram
  • Weigh less than 48 kilograms (105 lbs.)
  • Are pregnant or nursing

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 21 és 70 év között vagy?

Helyszínek itt: Egyesült Államok

  • Emory Brain Health CenterAtlanta, Egyesült ÁllamokCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

Posttraumatic stress disorder (PTSD) is a debilitating disorder. While effective treatments exist, some patients fail to receive the full benefits. Alternative treatment approaches are needed. 3,4-methylenedioxymethamphetamine (MDMA) is a medicine associated with feelings of closeness and love for others, empathy, insightfulness, and feelings of peace or well-being. Recent research combining one or two doses of MDMA with psychotherapy has shown improvements in PTSD symptoms.

A teljes eredeti leírásKevesebb

For the present study, the researchers will investigate MDMA in combination with Prolonged Exposure therapy (PE), a gold-standard treatment for PTSD. All participants receive MDMA on the second day of a 10-day PE treatment program in which a PE therapy session occurs each day. This study will occur at the Emory Brain Health Center. Potential participants will be recruited via community advertising and mental health referrals.

The research team will also collect psychophysiological data for exploratory analyses regarding how MDMA may improve PE treatment for PTSD. This is an important study as it is the first time MDMA will be combined with an evidence-based existing PTSD treatment.

The study population will consist of people who meet the criteria for PTSD and are medically appropriate for MDMA administration.

A vizsgálat csoportja

  • Medicine SessionA vizsgált kezelés

    3,4-methylenedioxymethamphetamine (MDMA) in combination with massed exposure therapy for PTSD

    Kezelés: MDMA

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Pilot Study of MDMA-Assisted Massed Exposure Therapy for PTSD (MDMA PE)
Kérdések a feltételekről
Forrás: NCT05746572: ki vehet részt
Publikációk
A regiszteradat frissítve
2026. július 8.